Works matching IS 23744677 AND DT 2025 AND VI 11 AND IP 1
Results: 26
Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00738-7
- By:
- Publication type:
- Article
Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00740-z
- By:
- Publication type:
- Article
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00739-6
- By:
- Publication type:
- Article
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00730-1
- By:
- Publication type:
- Article
Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00736-9
- By:
- Publication type:
- Article
Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00732-z
- By:
- Publication type:
- Article
Temporal evolution of breast cancer brain metastases treatments and outcomes.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00735-w
- By:
- Publication type:
- Article
The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00723-0
- By:
- Publication type:
- Article
Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00733-y
- By:
- Publication type:
- Article
Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00734-x
- By:
- Publication type:
- Article
A systematic review of determinants of breast cancer risk among women with benign breast disease.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-024-00703-w
- By:
- Publication type:
- Article
Clinico-pathological factors predicting pathological response in early triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00729-8
- By:
- Publication type:
- Article
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00720-3
- By:
- Publication type:
- Article
Spatial proximity of CD8<sup>+</sup> T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00728-9
- By:
- Publication type:
- Article
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00718-x
- By:
- Publication type:
- Article
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00727-w
- By:
- Publication type:
- Article
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00726-x
- By:
- Publication type:
- Article
Understanding metastasis mixed-treatment responses through genomic analyses.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00724-z
- By:
- Publication type:
- Article
Biological correlates associated with high-risk breast cancer patients identified using a computational method.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00725-y
- By:
- Publication type:
- Article
Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00722-1
- By:
- Publication type:
- Article
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00719-w
- By:
- Publication type:
- Article
Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00721-2
- By:
- Publication type:
- Article
Racial discrimination among women seeking breast cancer care.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00717-y
- By:
- Publication type:
- Article
Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-024-00715-6
- By:
- Publication type:
- Article
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling.
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-024-00716-5
- By:
- Publication type:
- Article
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER).
- Published in:
- NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-024-00708-5
- By:
- Publication type:
- Article